Atara Biotherapeutics (ATRA) Total Non-Current Liabilities (2013 - 2026)

Atara Biotherapeutics has reported Total Non-Current Liabilities for 14 years, with the latest figure at $15.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 86.11% year-over-year to $15.8 million; the trailing twelve-month figure through Mar 2026 stood at $15.8 million (down 86.11% YoY), and the FY2025 full-year result was $16.3 million, down 90.25% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $15.8 million, down from $16.3 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $259.2 million in Q1 2024, with the low at $15.8 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $165.7 million across 5 years, with a median of $175.7 million in 2022.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 40.11% — and 2025, when it tumbled 90.25%.
• Atara Biotherapeutics' Total Non-Current Liabilities stood at $244.2 million in 2022, then retreated by 5.96% to $229.7 million in 2023, then slipped by 27.12% to $167.4 million in 2024, then plunged by 90.25% to $16.3 million in 2025, then dropped by 2.94% to $15.8 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $15.8 million (Q1 2026), $16.3 million (Q4 2025), and $65.0 million (Q3 2025), per Business Quant data.